Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Eli Lilly and Company is conducting a clinical study titled ‘A Phase 3, Open-Label, Multicenter, Single-Arm Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Dulaglutide 3.0 mg and 4.5 mg in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes Mellitus.’ The study aims to explore additional dosing options for dulaglutide in young patients with Type 2 Diabetes, focusing on safety and efficacy.
The intervention being tested is dulaglutide, a drug administered subcutaneously. It is designed to manage blood sugar levels in pediatric patients with Type 2 Diabetes.
This interventional study employs a single-group assignment model with no masking, primarily aimed at treatment. It is a Phase 3 trial, indicating advanced testing stages for the drug’s efficacy and safety.
The study began on January 10, 2025, with the latest update submitted on July 7, 2025. These dates are crucial as they mark the study’s progress and ongoing recruitment status.
The study’s update could potentially influence Eli Lilly’s stock performance positively, as successful results may enhance investor confidence and market position. Given the competitive landscape in diabetes treatment, this study could also impact industry dynamics.
The study is currently ongoing, with further details available on the ClinicalTrials portal.